Navigation Links
AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results
Date:8/11/2009

adult growth hormone deficiency. - Announcement that data from the Company's safety study of the Phase 3 program in BPH with cetrorelix are expected to be disclosed ahead of schedule, from the fourth quarter 2009 to the third quarter of 2009. - Completion of a registered direct offering of US$10 million of units comprised of common shares and common share purchase warrants to certain institutional investors. Subsequent to Quarter-End July - Publication in Proceedings of the National Academy of Sciences of new data supporting the use of the Company's ghrelin receptor antagonist compound, AEZS-123, for the treatment of alcohol dependence. August - Keryx, the Company's partner and licensee for perifosine in the North American market, reached an agreement with the FDA regarding a Special Protocol Assessment on the design of a Phase 3 trial with perifosine in multiple myeloma.

Juergen Engel, Ph.D., AEterna Zentaris President and Chief Executive Officer, commented, "The quarter was marked by continued progress of our current Phase 3 program in BPH with cetrorelix. As part of this same program and with a sponsorship from sanofi-aventis, our partner for cetrorelix in the US market, we initiated the extension of our North American efficacy study. We also moved up disclosure of the safety trial results of this program ahead of schedule, from Q4 to Q3 2009. Furthermore, we presented data on some of our anticancer compounds at both the AACR and ASCO annual meetings, which underlined the breadth and potential of our product pipeline. Also, we were very pleased with Keryx's announcement that they expect to begin a Phase 3 trial with perifosine in multiple myeloma, following their recent SPA agreement with the FDA. We now look forward to disclosing first results of our Phase 3 program in BPH during the third quarter, as we continue to deploy a
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... DUBLIN , July 11, 2014 ... in part) in, into or from any jurisdiction where to ... of such jurisdiction.  Shire plc ("Shire" or the ... Bloomberg article this afternoon.  Shire confirms it has held a ... being made by Shire without the prior agreement or approval ...
(Date:7/11/2014)... 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. (Sunovion) today ... acetate) for use as a once-daily adjunctive therapy for ... who are not satisfactorily controlled with conventional therapy.  APTIOM ... under 18 years of age. Epilepsy ... according to Epilepsy Canada, it affects 0.6% of the ...
(Date:7/10/2014)... Product and process impurities in biopharmaceuticals ... are often “lost in the noise,” making their ... Dr. Rowel Tobias, Senior Scientist, Protein Chemistry at ... Quality at Nanotherapeutics, Inc., to lear about a ... and quantitation while achieving the required specificity and ...
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 Unraveling ... closer together. The Archer Family purchased a ... within DNA, but ended up with a lifetime of ... contained within the family members’ DNA genuinely brought the ... decided to search deeper into genetic history and prior ...
Breaking Biology Technology:Shire plc - Statement re: Media Speculation 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5
... Israel and JERSEY CITY, New Jersey, December 5, Rosetta ... the,development of microRNA-based diagnostics and therapeutics, announced today,that it ... on,Thursday, December 10, from 2:30-3:35 pm EST at the ... A live audio webcast of the ...
... developing solutions based on the products of newborn fibroblasts, will be ... of the 21st Century Breakthroughs for Biomedical Research series. , ... ... a regenerative medicine company developing solutions based on the products of ...
... (Nasdaq: BCRX ) announced today that the Company ... clinical data on BCX-4208 at the 50th American Society of ... Francisco, CA from December 6-9, 2008. Forodesine HCl and ... , The schedule for BioCryst,s poster ...
Cached Biology Technology:Rosetta Genomics to Webcast Panel Presentation at RBC Capital Markets 2008 Healthcare Conference 2Rosetta Genomics to Webcast Panel Presentation at RBC Capital Markets 2008 Healthcare Conference 3Histogen Featured on Economic Report Television Series 2BioCryst to Present Three Posters During the 50th American Society of Hematology Annual Meeting and Exposition 2BioCryst to Present Three Posters During the 50th American Society of Hematology Annual Meeting and Exposition 3
(Date:7/11/2014)... of researchers, including scientists from the Max Planck Institute ... a major step in understanding photosynthesis, the process by ... oxygen in its atmosphere and which is therefore crucial ... , The researchers report the first direct visualization of ... step in which a specific protein complex, photosystem II, ...
(Date:7/11/2014)... Recent evidence has demonstrated that transplantation of mesenchymal stem ... rat or mouse models of Alzheimer,s disease (AD) and ... cerebral ischemia. Few studies are reported on the therapeutic ... with AD and on the effect on oxidative injury ... Yufang Yan and her team, School of Life Sciences, ...
(Date:7/11/2014)... Research and Markets has announced the addition ... Analysis Size Share Growth Trends and Forecast to 2019" ... http://photos.prnewswire.com/prnh/20130307/600769 The rising number of ... high level security in both private and public sector. ... and passwords, tokens etc. are vulnerable to attacks. Biometrics ...
Breaking Biology News(10 mins):A first direct glimpse of photosynthesis in action 2International Biometrics Technology Market - Industry Analysis Size Share Growth Trends and Forecast to 2019 2
... from the University of Liverpool's School of Biological Sciences have ... Gormley's 'Another Place' art installation on Crosby Beach have become ... barnacle - Elminius modestus. , Although the barnacles have been ... from half way across the world on the coasts of ...
... threat against the viabi lity of the Scandinavian wolf ... journal PLoS ONE now demonstrates that inbreeding is not ... show that it is the most genetically variable wolf ... important consequence of this action of natural selection is ...
... device currently used for intestinal research, the colonsope, causes ... has been developed, inspired by the way in which ... her PhD degree from TU Delft based on this ... difficult area to navigate through with a medical device. ...
Cached Biology News:Living laboratory found on shoreline statues 2Wolves are suffering less from inbreeding than expected 2Like a snail through the intestinal canal 2